| Field | Specification |
|---|---|
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C23H24N4O4S |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
SBI-993 is an analog of SBI-477 with improved potency and pharmacokinetic properties suited to in vivo bioavailability. It stimulates insulin signaling by deactivating the transcription factor MondoA[1]. It is supplied as a white to off-white solid (C23H24N4O4S, MW 452.53) at 98.79% purity.
Physical & Chemical Properties
| CAS Number | 2073059-82-0 |
|---|---|
| Molecular Formula | C23H24N4O4S |
| Molecular Weight | 452.53 g/mol |
| Purity | 98.79% |
| Appearance | Solid |
| Color | White to off-white |
| SMILES | O=C(NC1=NC(C2=CC=C(OC)C=C2)=CS1)C3=CC=C(NCC(N4CCOCC4)=O)C=C3 |
| Solubility | In Vitro: DMSO: 100 mg/mL (220.98 mM; Requires sonication and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | 4°C, protect from light. In solvent: -80°C, 6 months; -20°C, 1 month (protect from light). |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 100 mg/mL (220.98 mM) | requires sonication and warming and heat to 60°C; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); protect from light; avoid repeated freeze-thaw cycles.
Data provided by the manufacturer.
In Vitro
In human myotubes, SBI-993 lowers expression of thioredoxin-interacting protein (TXNIP) and arrestin domain-containing 4 (ARRDC4)[1].
In Vivo
Treatment with SBI-993 (50 mg/kg; s.c.; daily; for 7 days) lowers expression of triacylglyceride synthesis and lipogenic genes in muscle and liver alike. SBI-993 also lowers Txnip and Arrdc4 expression. In liver, SBI-993 reduces occupation of the Txnip and pyruvate kinase (Pklr) gene promoters by both ChREBP and MondoA[1]. SBI-993 improves insulin signaling in both muscle and liver after an acute insulin challenge[1].
| Animal Model | Mice are fed a 60% high-fat diet (HFD)[1] |
|---|---|
| Dosage | 50 mg/kg |
| Administration | s.c.; daily; for 7 days |
| Result | Reduced the expression of triacylglyceride synthesis and lipogenic genes in both muscle and liver. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
